Family Nurse Practitioner
(FNP) ANCC & AANP Exam
Bank – OB/GYN + Cardiac
2026 Edition
PART I: THE PRIMER
Mastering the intersection of high-acuity cardiovascular and obstetrical-gynecological care is the
definitive hallmark of an elite Family Nurse Practitioner. This gauntlet replaces academic
memorization with the clinical intuition required to navigate 2026’s rigorous, high-stakes practice
environments.
● AHA 2026 HTN Threshold: BP ≥130/80 mmHg is hypertension; initiate pharmacotherapy
at Stage 1 if the PREVENT risk score is ≥7.5%.
● HF GDMT 2026: SGLT2 inhibitors are absolute first-line therapy for all heart failure
phenotypes (HFrEF, HFmrEF, HFpEF), completely independent of diabetes status.
● ACOG 2026 Cervical Screening: Primary hrHPV testing every 5 years (ages 30-65) is
preferred; patient self-collection is officially validated and reimbursable.
● Breast Cancer USPSTF 2026: Biennial screening mammography is strictly mandated
starting at age 40 for average-risk women.
● Maternal RSV 2026: Administer single-dose RSVpreF (Abrysvo) at 32–36 weeks
gestation (September–January) to bypass infant immunization.
PART II: THE ELITE TEST BANK
Q1: A 54-year-old male presents for an annual exam. His blood pressure averages 136/84
mmHg across two visits. His PREVENT calculator 10-year total cardiovascular risk score
is 8.2%. He has no history of clinical ASCVD. According to the 2026 AHA/ACC guidelines,
what is the appropriate intervention? A) Recommend 6 months of lifestyle modifications
before reassessing. B) Initiate a single first-line antihypertensive medication alongside lifestyle
modifications. C) Initiate dual antihypertensive therapy in a single-pill combination. D) Order a
coronary artery calcium (CAC) score to determine if pharmacotherapy is warranted.
● The Answer: B) Initiate a single first-line antihypertensive medication alongside lifestyle
modifications.
● Distractor Analysis: Option A is a dangerous amateur trap; while lifestyle modifications
are core, the 2026 guidelines dictate immediate pharmacotherapy for Stage 1 HTN if the
PREVENT score is ≥7.5%. Option C is strictly reserved for Stage 2 HTN (≥140/90
mmHg). Option D delays mandatory treatment for a patient who already meets the
validated risk threshold.
● The Mentor's Analysis: The 2026 shift from the Pooled Cohort Equations (PCE) to the
, PREVENT equation lowered the action threshold from 10% to 7.5%. Professional intuition
dictates that Stage 1 HTN (130-139/80-89) paired with a PREVENT score ≥7.5% requires
immediate pharmacologic blockade to prevent downstream vascular shearing and
myocardial remodeling.
| PREVENT Score Threshold | Stage 1 HTN (130-139/80-89) Action | Stage 2 HTN (≥140/90)
Action | | :--- | :--- | :--- | | < 7.5% | Lifestyle modifications for 3-6 months | Dual-agent
pharmacotherapy | | ≥ 7.5% | Single-agent pharmacotherapy + Lifestyle | Dual-agent
pharmacotherapy |
Q2: A 38-year-old G2P1 at 32 weeks gestation with a history of moderate mitral stenosis
presents with sudden onset dyspnea, orthopnea, and pink frothy sputum. Her BP is
128/78 mmHg, HR 110 bpm. What is the precise mechanistic cause of her acute
decompensation? A) Preeclampsia with severe features triggering pulmonary edema. B)
Progesterone-induced respiratory alkalosis transitioning to failure. C) Fixed cardiac output
failure in the face of peak plasma volume and decreased diastolic filling time. D) Placental
abruption leading to systemic inflammatory response syndrome.
● The Answer: C) Fixed cardiac output failure in the face of peak plasma volume and
decreased diastolic filling time.
● Distractor Analysis: Option A is the novice's default for any pregnant patient with
respiratory distress, but her BP is normal, negating severe preeclampsia. Option B
causes dyspnea but not frothy sputum (edema). Option D is clinically unsupported by the
symptom matrix.
● The Mentor's Analysis: Pregnancy is the ultimate hemodynamic stress test. Plasma
volume peaks at 32 weeks. To maintain BP against decreasing systemic vascular
resistance, cardiac output must increase by 30-50%. A stenotic mitral valve represents a
fixed orifice; tachycardia further decreases diastolic filling time, instantly backing up
hydrostatic pressure into the left atrium and pulmonary bed, causing flash pulmonary
edema.
Q3: A 42-year-old average-risk female presents for her well-woman exam. She has not
had a mammogram. She states, "I heard I can wait until I am 50." Based on the finalized
2026 USPSTF guidelines, how should the clinician advise her? A) "You are correct; we will
begin biennial screening at age 50." B) "We must begin annual screening today, as early
detection is critical." C) "We will begin biennial screening mammography today, as the starting
age is now 40." D) "We will begin annual screening with breast MRI, followed by a mammogram
at age 45."
● The Answer: C) "We will begin biennial screening mammography today, as the starting
age is now 40."
● Distractor Analysis: Option A relies on outdated 2016 guidelines. Option B incorrectly
mandates annual screening; the USPSTF mandate is biennial, though ACOG allows
annual based on shared decision-making. Option D misapplies high-risk MRI screening
protocols to an average-risk patient.
● The Mentor's Analysis: The definitive standard of care shifted in 2024/2026 due to the
2% annual increase of invasive breast cancer in the 40-49 age cohort. The USPSTF
explicitly mandates biennial screening starting at age 40 for all average-risk women to
capture tumors during the critical 2-2.4 year sojourn time window.
Guideline Body Starting Age (Average Frequency Modality
Risk)
USPSTF (2026) 40 Biennial Mammography
, Guideline Body Starting Age (Average Frequency Modality
Risk)
ACOG (2026) 40 Annual or Biennial Mammography
ACS (2026) 40 (Optional), 45 Annual Mammography
(Mandatory)
Q4: A 68-year-old male with Heart Failure with Preserved Ejection Fraction (HFpEF; LVEF
55%), hypertension, and a BMI of 32 presents for optimization. He is not diabetic. Which
medication must be initiated to reduce heart failure hospitalizations and cardiovascular
mortality? A) Lisinopril B) Empagliflozin C) Semaglutide D) Metoprolol Succinate
● The Answer: B) Empagliflozin
● Distractor Analysis: Option A and D are foundational for HFrEF, but lack specific
mortality benefit in pure HFpEF. Option C (a GLP-1) aids weight loss but SGLT2 inhibitors
hold the definitive Class IIa/I guideline mandate for reducing HFpEF mortality.
● The Mentor's Analysis: The 2022/2026 AHA/ACC/HFSA guidelines cemented SGLT2
inhibitors (Empagliflozin/Dapagliflozin) as the foundational pillar for all heart failure
phenotypes, completely independent of diabetes status. They mechanically unload the
ventricle, reduce preload, and improve myocardial energetics. Withholding this class
because the patient is euglycemic represents a failure of modern cardiovascular practice.
Q5: A 33-year-old female presents for a routine cervical cancer screening. She is highly
anxious and refuses a pelvic speculum examination due to a history of severe trauma.
Under 2026 HRSA guidelines, what is the standard-of-care alternative? A) Defer screening
until she is comfortable and document refusal. B) Perform a transvaginal ultrasound to assess
the cervix. C) Provide the patient with a self-collection kit for primary hrHPV testing. D) Order a
serum HPV antibody titer.
● The Answer: C) Provide the patient with a self-collection kit for primary hrHPV testing.
● Distractor Analysis: Option A constitutes clinical neglect now that an alternative exists.
Option B cannot detect cervical dysplasia. Option D is fictitious in modern oncology.
● The Mentor's Analysis: In 2026, HRSA and the USPSTF formally validated
patient-collected vaginal swabs for high-risk HPV (hrHPV) as an entirely equivalent
primary screening tool for average-risk women aged 30-65. This eliminates the speculum
barrier for trauma survivors, achieving high sensitivity for persistent oncogenic viral strains
while maintaining mandatory insurance coverage.
Q6: A 28-year-old G1P0 at 28 weeks gestation presents with an asthma exacerbation. Her
arterial blood gas reveals: pH 7.44, PaCO2 30 mmHg, HCO3 20 mEq/L. How do you
interpret these findings? A) Uncompensated respiratory alkalosis indicating impending
maternal exhaustion. B) Metabolic acidosis secondary to fetal hypoxia. C) Normal compensated
respiratory alkalosis of pregnancy. D) Severe CO2 retention requiring immediate intubation.
● The Answer: C) Normal compensated respiratory alkalosis of pregnancy.
● Distractor Analysis: Option A misreads the compensation (HCO3 is appropriately down,
buffering the pH). Option B is a novice misinterpretation of the low HCO3. Option D is
lethal; a PaCO2 of 30 is normal in pregnancy. A PaCO2 of 40 mmHg in pregnancy
actually represents retention and impending respiratory failure.
● The Mentor's Analysis: Progesterone drives a 40% increase in tidal volume, blowing off
CO2 and lowering baseline PaCO2 to 27-32 mmHg. The kidneys compensate by
excreting bicarbonate (normal 18-22 mEq/L in pregnancy). Knowing this native physiology
prevents misdiagnosing a perfectly normal pregnant ABG as pathological, or conversely,
ignoring a PaCO2 of 40 mmHg, which signals catastrophic respiratory fatigue.
(FNP) ANCC & AANP Exam
Bank – OB/GYN + Cardiac
2026 Edition
PART I: THE PRIMER
Mastering the intersection of high-acuity cardiovascular and obstetrical-gynecological care is the
definitive hallmark of an elite Family Nurse Practitioner. This gauntlet replaces academic
memorization with the clinical intuition required to navigate 2026’s rigorous, high-stakes practice
environments.
● AHA 2026 HTN Threshold: BP ≥130/80 mmHg is hypertension; initiate pharmacotherapy
at Stage 1 if the PREVENT risk score is ≥7.5%.
● HF GDMT 2026: SGLT2 inhibitors are absolute first-line therapy for all heart failure
phenotypes (HFrEF, HFmrEF, HFpEF), completely independent of diabetes status.
● ACOG 2026 Cervical Screening: Primary hrHPV testing every 5 years (ages 30-65) is
preferred; patient self-collection is officially validated and reimbursable.
● Breast Cancer USPSTF 2026: Biennial screening mammography is strictly mandated
starting at age 40 for average-risk women.
● Maternal RSV 2026: Administer single-dose RSVpreF (Abrysvo) at 32–36 weeks
gestation (September–January) to bypass infant immunization.
PART II: THE ELITE TEST BANK
Q1: A 54-year-old male presents for an annual exam. His blood pressure averages 136/84
mmHg across two visits. His PREVENT calculator 10-year total cardiovascular risk score
is 8.2%. He has no history of clinical ASCVD. According to the 2026 AHA/ACC guidelines,
what is the appropriate intervention? A) Recommend 6 months of lifestyle modifications
before reassessing. B) Initiate a single first-line antihypertensive medication alongside lifestyle
modifications. C) Initiate dual antihypertensive therapy in a single-pill combination. D) Order a
coronary artery calcium (CAC) score to determine if pharmacotherapy is warranted.
● The Answer: B) Initiate a single first-line antihypertensive medication alongside lifestyle
modifications.
● Distractor Analysis: Option A is a dangerous amateur trap; while lifestyle modifications
are core, the 2026 guidelines dictate immediate pharmacotherapy for Stage 1 HTN if the
PREVENT score is ≥7.5%. Option C is strictly reserved for Stage 2 HTN (≥140/90
mmHg). Option D delays mandatory treatment for a patient who already meets the
validated risk threshold.
● The Mentor's Analysis: The 2026 shift from the Pooled Cohort Equations (PCE) to the
, PREVENT equation lowered the action threshold from 10% to 7.5%. Professional intuition
dictates that Stage 1 HTN (130-139/80-89) paired with a PREVENT score ≥7.5% requires
immediate pharmacologic blockade to prevent downstream vascular shearing and
myocardial remodeling.
| PREVENT Score Threshold | Stage 1 HTN (130-139/80-89) Action | Stage 2 HTN (≥140/90)
Action | | :--- | :--- | :--- | | < 7.5% | Lifestyle modifications for 3-6 months | Dual-agent
pharmacotherapy | | ≥ 7.5% | Single-agent pharmacotherapy + Lifestyle | Dual-agent
pharmacotherapy |
Q2: A 38-year-old G2P1 at 32 weeks gestation with a history of moderate mitral stenosis
presents with sudden onset dyspnea, orthopnea, and pink frothy sputum. Her BP is
128/78 mmHg, HR 110 bpm. What is the precise mechanistic cause of her acute
decompensation? A) Preeclampsia with severe features triggering pulmonary edema. B)
Progesterone-induced respiratory alkalosis transitioning to failure. C) Fixed cardiac output
failure in the face of peak plasma volume and decreased diastolic filling time. D) Placental
abruption leading to systemic inflammatory response syndrome.
● The Answer: C) Fixed cardiac output failure in the face of peak plasma volume and
decreased diastolic filling time.
● Distractor Analysis: Option A is the novice's default for any pregnant patient with
respiratory distress, but her BP is normal, negating severe preeclampsia. Option B
causes dyspnea but not frothy sputum (edema). Option D is clinically unsupported by the
symptom matrix.
● The Mentor's Analysis: Pregnancy is the ultimate hemodynamic stress test. Plasma
volume peaks at 32 weeks. To maintain BP against decreasing systemic vascular
resistance, cardiac output must increase by 30-50%. A stenotic mitral valve represents a
fixed orifice; tachycardia further decreases diastolic filling time, instantly backing up
hydrostatic pressure into the left atrium and pulmonary bed, causing flash pulmonary
edema.
Q3: A 42-year-old average-risk female presents for her well-woman exam. She has not
had a mammogram. She states, "I heard I can wait until I am 50." Based on the finalized
2026 USPSTF guidelines, how should the clinician advise her? A) "You are correct; we will
begin biennial screening at age 50." B) "We must begin annual screening today, as early
detection is critical." C) "We will begin biennial screening mammography today, as the starting
age is now 40." D) "We will begin annual screening with breast MRI, followed by a mammogram
at age 45."
● The Answer: C) "We will begin biennial screening mammography today, as the starting
age is now 40."
● Distractor Analysis: Option A relies on outdated 2016 guidelines. Option B incorrectly
mandates annual screening; the USPSTF mandate is biennial, though ACOG allows
annual based on shared decision-making. Option D misapplies high-risk MRI screening
protocols to an average-risk patient.
● The Mentor's Analysis: The definitive standard of care shifted in 2024/2026 due to the
2% annual increase of invasive breast cancer in the 40-49 age cohort. The USPSTF
explicitly mandates biennial screening starting at age 40 for all average-risk women to
capture tumors during the critical 2-2.4 year sojourn time window.
Guideline Body Starting Age (Average Frequency Modality
Risk)
USPSTF (2026) 40 Biennial Mammography
, Guideline Body Starting Age (Average Frequency Modality
Risk)
ACOG (2026) 40 Annual or Biennial Mammography
ACS (2026) 40 (Optional), 45 Annual Mammography
(Mandatory)
Q4: A 68-year-old male with Heart Failure with Preserved Ejection Fraction (HFpEF; LVEF
55%), hypertension, and a BMI of 32 presents for optimization. He is not diabetic. Which
medication must be initiated to reduce heart failure hospitalizations and cardiovascular
mortality? A) Lisinopril B) Empagliflozin C) Semaglutide D) Metoprolol Succinate
● The Answer: B) Empagliflozin
● Distractor Analysis: Option A and D are foundational for HFrEF, but lack specific
mortality benefit in pure HFpEF. Option C (a GLP-1) aids weight loss but SGLT2 inhibitors
hold the definitive Class IIa/I guideline mandate for reducing HFpEF mortality.
● The Mentor's Analysis: The 2022/2026 AHA/ACC/HFSA guidelines cemented SGLT2
inhibitors (Empagliflozin/Dapagliflozin) as the foundational pillar for all heart failure
phenotypes, completely independent of diabetes status. They mechanically unload the
ventricle, reduce preload, and improve myocardial energetics. Withholding this class
because the patient is euglycemic represents a failure of modern cardiovascular practice.
Q5: A 33-year-old female presents for a routine cervical cancer screening. She is highly
anxious and refuses a pelvic speculum examination due to a history of severe trauma.
Under 2026 HRSA guidelines, what is the standard-of-care alternative? A) Defer screening
until she is comfortable and document refusal. B) Perform a transvaginal ultrasound to assess
the cervix. C) Provide the patient with a self-collection kit for primary hrHPV testing. D) Order a
serum HPV antibody titer.
● The Answer: C) Provide the patient with a self-collection kit for primary hrHPV testing.
● Distractor Analysis: Option A constitutes clinical neglect now that an alternative exists.
Option B cannot detect cervical dysplasia. Option D is fictitious in modern oncology.
● The Mentor's Analysis: In 2026, HRSA and the USPSTF formally validated
patient-collected vaginal swabs for high-risk HPV (hrHPV) as an entirely equivalent
primary screening tool for average-risk women aged 30-65. This eliminates the speculum
barrier for trauma survivors, achieving high sensitivity for persistent oncogenic viral strains
while maintaining mandatory insurance coverage.
Q6: A 28-year-old G1P0 at 28 weeks gestation presents with an asthma exacerbation. Her
arterial blood gas reveals: pH 7.44, PaCO2 30 mmHg, HCO3 20 mEq/L. How do you
interpret these findings? A) Uncompensated respiratory alkalosis indicating impending
maternal exhaustion. B) Metabolic acidosis secondary to fetal hypoxia. C) Normal compensated
respiratory alkalosis of pregnancy. D) Severe CO2 retention requiring immediate intubation.
● The Answer: C) Normal compensated respiratory alkalosis of pregnancy.
● Distractor Analysis: Option A misreads the compensation (HCO3 is appropriately down,
buffering the pH). Option B is a novice misinterpretation of the low HCO3. Option D is
lethal; a PaCO2 of 30 is normal in pregnancy. A PaCO2 of 40 mmHg in pregnancy
actually represents retention and impending respiratory failure.
● The Mentor's Analysis: Progesterone drives a 40% increase in tidal volume, blowing off
CO2 and lowering baseline PaCO2 to 27-32 mmHg. The kidneys compensate by
excreting bicarbonate (normal 18-22 mEq/L in pregnancy). Knowing this native physiology
prevents misdiagnosing a perfectly normal pregnant ABG as pathological, or conversely,
ignoring a PaCO2 of 40 mmHg, which signals catastrophic respiratory fatigue.
